
Mounjaro and Zepbound drive Eli Lilly past Wall Street expectations
Strong demand for Mounjaro and Zepbound helped Eli Lilly report $23 billion in second-quarter revenue, surpassing Wall Street expectations and prompting the company to raise its full-year forecast.





